Results 201 to 210 of about 88,666 (249)

Role of microRNA-486-5p as Biomarker Response in Cell Line K562 of Chronic Myeloid Leukemia. [PDF]

Asian Pac J Cancer Prev
Jha JP, Sinha DK, Singh S, Kumari R.
europepmc   +1 more source

A PI3K Inhibitor with Low Cardiotoxicity and Its Synergistic Inhibitory Effect with Gilteritinib in Acute Myelogenous Leukemia (AML) Cells. [PDF]

Molecules
Wu T, Chen Y, Gong Y, Lu M, Yang C, Yang Y, Ling Y, Zhou Y.   +7 more
europepmc   +1 more source

Uncovering non-autoimmune hypothyroidism: A case report of rhabdomyolysis and myocarditis mimicking acute coronary syndrome. [PDF]

Medicine (Baltimore)
Jeon H, Lee S, Jung S, Jang H, Chang SH, Kim HJ.   +5 more
europepmc   +1 more source

Extracellular vesicles enhance the in vivo antitumor effects of millettia species-derived compounds in chronic myelogenous leukemia therapy. [PDF]

Front Chem
Xie Z, Cheng X, Mao J, Zhu Y, Li L, Mei Z.   +5 more
europepmc   +1 more source

Thyroid Cancer in Childhood Leukemia Survivors: A Systematic Review of the Incidence and Survival Outcomes. [PDF]

J Clin Med
Tsinopoulou VR, Kotanidou EP, Kolanis S, Tragiannidis A, Hatzipantelis E, Galli-Tsinopoulou A.   +5 more
europepmc   +1 more source

Washington University Medical Alumni Quarterly, January 1944 [PDF]

, 1944

core   +1 more source

A lncRNA signature associated with endoplasmic reticulum stress supports prognostication and prediction of drug resistance in acute myelogenous leukemia. [PDF]

Transl Cancer Res
Fu Y, Wang S, Meng L, Liu Y.
europepmc   +1 more source

Aspergillus fumigatus Bloodstream Infection in the Absence of Classic Risk Factors: Expanding the Spectrum of Invasive Aspergillosis. [PDF]

Cureus
Molina M, Javed N, Penikilapate S, Alao O.   +3 more
europepmc   +1 more source

An efficient leukemia prediction method using machine learning and deep learning with selected features. [PDF]

PLoS One
Ilyas M, Ramzan M, Deriche M, Mahmood K, Naz A.   +4 more
europepmc   +1 more source

Co-Occurrence of Jak2-Positive Myelofibrosis and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. [PDF]

Mediterr J Hematol Infect Dis
Paciaroni K, Campagna S, Villiva N, Maffini E, Celesti F, Tordi A, Lombardi M, Dragonetti G, di Toritto TC.   +8 more
europepmc   +1 more source